Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07787208
PHASE1

A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors

Sponsor: Ono Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

This study is to evaluate the tolerability and safety of ONO-7429 in participants with unresectable advanced or recurrent solid tumors.

Official title: A Phase 1, Open-label, Dose Escalation Study to Investigate the Safety and Tolerability of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2026-06-19

Completion Date

2030-03

Last Updated

2026-08-26

Healthy Volunteers

No

Conditions

Interventions

DRUG

ONO-7429

Specified dose on specified days

Locations (10)

National Cancer Center Hospital East

Kashiwa, Chiba, Japan

Gunma University Hospital

Maebashi, Gunma, Japan

Niigata Cancer Center Hospital

Niigata, Niigata, Japan

Kansai Medical University Hospital

Hirakata, Osaka, Japan

Osaka International Cancer Institute

Osaka, Osaka, Japan

Kindai University Hospital

Sakai, Osaka, Japan

Saitama Medical University International Medical Center

Hidaka, Saitama, Japan

Shizuoka Cancer Center

Sunto-gun, Shizuoka, Japan

National Cancer Center Hospital

Chuo-ku, Tokyo, Japan

The Cancer Institute Hospital of JFCR

Koto-ku, Tokyo, Japan